Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.73 |
| ▸ | HTR2A | P28223 | 3/20 | 0.65 |
| ▸ | HTR1A | P08908 | 2/20 | 0.56 |
| ▸ | MPO | P05164 | 8/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27661274 | 0.86 | HTR2A (0.71) | GPR84HTR2AHTR1AMPOHTR2C | |
| SCHEMBL3741788 | 0.85 | GPR84 (0.73) | GPR84HTR2AHTR1AMPOHTR2C | |
| SCHEMBL27929607 | 0.85 | GPR84 (1.00) | GPR84HTR2AHTR1AMPOHTR2C | |
| SCHEMBL31415125 | 0.81 | HTR2A (0.75) | GPR84HTR2AHTR1AMPOHTR2C | |
| SCHEMBL6846117 | 0.81 | GPR84 (0.73) | GPR84HTR2AHTR1AMPOHTR2C | |
| SCHEMBL24199403 | 0.81 | GPR84 (0.73) | GPR84HTR2AHTR1AMPOHTR2C | |
| SCHEMBL5636918 | 0.80 | HTR2A (0.67) | GPR84HTR2AHTR1AMPOTRPM8 | |
| SCHEMBL4496642 | 0.79 | HTR2A (0.71) | GPR84HTR2AHTR1AMPOHTR2C | |
| SCHEMBL30952647 | 0.79 | HTR2A (1.00) | GPR84HTR2AHTR1AMPOHTR2C | |
| SCHEMBL743153 | 0.79 | HTR2A (1.00) | GPR84HTR2AHTR1AMPOHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120094977-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2012-04-19 | — | — | US | claimed |
| EP-1663962-A4 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORP (US) | 2007-08-22 | — | — | EP | claimed |
| JP-2007503392-A | — | — | 2007-02-22 | — | — | JP | claimed |
| EP-1663962-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2006-06-07 | — | — | EP | claimed |
| US-20050054651-A1 | Compositions and methods for the treatment of disease associated with Trp-p8 expression | DENDREON CORPORATION (US) | 2005-03-10 | — | — | US | claimed |
| WO-2005020897-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2005-03-10 | — | — | WO | claimed |
| CN-106458889-A | Novel polymorphic forms of N- [2- (6-fluoro-1H-indol-3-yl) ethyl ] -3- (2,2,3, 3-tetrafluoropropoxy) benzylamine hydrochloride for the treatment of Alzheimer's disease | H.隆德贝克有限公司 | 2017-02-22 | — | — | CN | disclosed |
| US-20150266810-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | V-BAC HOLDING CORP. (CA) | 2015-09-24 | — | — | US | disclosed |
| US-20130190296-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2013-07-25 | — | — | US | disclosed |
| US-8389730-B2 | Compositions and methods for the treatment of disease associated with TRP-P8 expression | DENDREON CORPORATION (US) | 2013-03-05 | — | — | US | disclosed |
| US-8362264-B2 | Tryptophan antagonist; anticancer agents | DENDREON CORPORATION (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120094977-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2012-04-19 | — | — | US | disclosed |
| EP-1663962-A4 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORP (US) | 2007-08-22 | — | — | EP | disclosed |
| EP-1663962-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050054651-A1 | Compositions and methods for the treatment of disease associated with Trp-p8 expression | DENDREON CORPORATION (US) | 2005-03-10 | — | — | US | disclosed |
| WO-2005020897-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2005-03-10 | — | — | WO | disclosed |
| US-4138489-A | FORMALDEHYDE, QUATERNIZATION | AGENCE NATIONALE DE VALORISATION DE LA RECHERCHE (ANVAR) (FR) | 1979-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190296-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | TRPC4, TRPC3, TRPC1 | GPR84 82/4885HTR2A 348/4885HTR1A 155/4885 |
| US-20120094977-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | TRPC4, TRPC3, TRPC1 | GPR84 40/4885HTR2A 168/4885HTR1A 74/4885 |
| US-20150266810-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | TRPC4, TRPC3, TRPC1 | GPR84 106/4885HTR2A 502/4885HTR1A 234/4885 |
| US-20050054651-A1 | Compositions and methods for the treatment of disease associated with Trp-p8 expression | TRPC4, TRPC3, TRPC1 | GPR84 40/4885HTR2A 168/4885HTR1A 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.